Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA
- 1- 3- and 6-Month Formulations
- A new Treatment for Prostate Cancer Patients in
Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, and Mepha Pharma A.G. (Mepha), announce the signature of an exclusive distribution agreement in
"We are pleased that Mepha has recognised the added value and comfort that Pamorelin(R) LA will provide for prostate cancer patients in
expertise in the commercialisation of high quality products."
"We are happy to be working alongside an innovative drug developer like Debiopharm for the distribution of Pamorelin(R) LA in
About Pamorelin(R) LA
Triptorelin, a luteinizing hormone releasing hormone (LHRH) agonist, was licensed-in from
Debiopharm has also developed a 6-month formulation of triptorelin, which has been submitted to the European and the U.S. regulatory authorities and will be submitted to Swissmedic in Q3 2009.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.
Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in
Debio R.P., is a pharmaceutical research, development and production facility inspected by the FDA and Swissmedic. Each year, 300'000 patients worldwide are treated with products that are developed or produced there, with a response rate to treatment of 95%. Debio R.P. is part of Debiopharm Group and employs 120 people, of whom half have university or engineering background.
For more information on Debiopharm Group, please visit: http://www.debiopharm.com.
Mepha is the leading company in the Swiss generic market and is strongly present in all distribution channels (pharmacists, medical doctors, hospitals). Mepha develops and produces attractive medical products and services in
Debiopharm S.A. Contact: Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 firstname.lastname@example.org Debio R.P. Contact: Bertrand Ducrey CEO Tel. : +41(0)27-721-79-00 Fax : +41(0)27-721-79-01 Email : email@example.com Mepha Contact: Mepha Pharma AG Christoph Herzog Head of corporate communication Tel: +41(0)61-705-44-71 Fax: +41(0)61-705-42-33 Email: firstname.lastname@example.org Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 email@example.com In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel: +1-212-845-4292 Fax: +1-212-845-4260 firstname.lastname@example.org
SOURCE The Debiopharm Group